+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Leukapheresis Market by Component, Application, End User, Disease Indication, Technology - Global Forecast to 2030- Product Image
Leukapheresis Market by Component, Application, End User, Disease Indication, Technology - Global Forecast to 2030- Product Image
Sale

Leukapheresis Market by Component, Application, End User, Disease Indication, Technology - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5322961
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Leukapheresis Market grew from USD 61.62 million in 2024 to USD 67.79 million in 2025. It is expected to continue growing at a CAGR of 9.75%, reaching USD 107.68 million by 2030.

Setting the Stage for Innovations in Leukapheresis

Leukapheresis has emerged as a critical procedure in both clinical and research settings, enabling the selective removal and collection of white blood cells for therapeutic applications. Historically leveraged in treatment protocols for hematologic malignancies, the process now underpins advancements in immunotherapy, cellular therapies, and precision diagnostics. As healthcare systems worldwide integrate personalized medicine, the demand for efficient and reliable leukapheresis platforms continues to intensify.

This executive summary distills key insights from a comprehensive evaluation of market dynamics, technological innovations, and regulatory developments shaping the leukapheresis landscape. Readers will gain clarity on transformative shifts, the implications of recent policy measures, and granular segmentation analyses that reveal high-potential opportunities. Furthermore, strategic recommendations and a transparent overview of the research approach provide actionable guidance for stakeholders seeking to navigate emerging challenges and capitalize on growth vectors.

Transformative Shifts Redefining Leukapheresis Applications

Recent years have witnessed a cascade of technological breakthroughs that are redefining leukapheresis capabilities. Automated systems now feature enhanced flow control mechanisms, enabling precise modulation of cellular separation parameters. Real-time monitoring devices integrate advanced sensor technologies to track anticoagulant levels and component purity, ensuring consistent product quality. These advances are complemented by novel consumable designs, where next-generation anticoagulants reduce procedural complexity and customized kits streamline workflow.

Simultaneously, the expansion of clinical applications has extended beyond traditional hematology into autoimmune disorders and solid tumor immunotherapies. Regulatory agencies are increasingly receptive to data supporting novel indications, accelerating the adoption of leukapheresis in emerging therapeutic arenas. Moreover, digital health integration-through cloud-based data analytics and remote diagnostics-is fostering new service models that reduce hospital stays and enhance patient engagement. Together, these transformative shifts are converging to create a more agile, data-driven, and patient-centric leukapheresis environment.

Assessing the Cumulative Impact of US Tariffs on Leukapheresis

The introduction of new import tariffs in the United States during 2025 has reverberated across the leukapheresis supply chain. Equipment manufacturers faced increased duties on critical components, driving cost pressures that some have absorbed through operational efficiencies while others have passed along incremental expenses to end users. Consumable suppliers experienced similar headwinds, prompting several to diversify sourcing strategies and seek alternative materials that comply with tariff regulations without compromising quality.

As a result, many stakeholders are actively reshaping their procurement footprints, relocating assembly operations closer to domestic markets or forging partnerships with local distributors. These adjustments mitigate lead times and stabilize price volatility, yet they also necessitate investments in new regulatory certifications and quality assurance processes. Healthcare providers are adapting by renegotiating service agreements and exploring bundled solutions that offer predictable cost structures. In sum, the cumulative impact of 2025 tariff changes has catalyzed a shift toward supply chain resilience and strategic collaboration.

Uncovering Market Opportunities Through Segmentation Analysis

A granular look at market segmentation reveals varied demand drivers across product categories. When dissecting the component tier, consumables dominate short-term expenditure due to the recurring nature of anticoagulants and kits, whereas capital investments in apheresis systems and monitoring devices determine long-term infrastructure planning. Each segment exhibits distinct adoption curves, with anticoagulant innovations prompting frequent protocol updates and system upgrades timed over multi-year cycles.

Application-based segmentation further illuminates high-growth niches. Diagnostic use cases hinge on advancements in blood analysis and immune monitoring to inform treatment decisions, while research applications in cellular therapy and stem cell research depend on precise collection protocols. Therapeutic deployment remains anchored in oncology and autoimmune interventions, yet the breakdown of indications underscores divergent procedural frequencies and reimbursement pathways.

End-user insights highlight the purchasing behavior of major institutions. Hospitals leverage scale and negotiate volume-based agreements, research institutes prioritize customizable platforms for experimental work, and specialty clinics seek turnkey solutions that integrate seamlessly with outpatient services. Meanwhile, disease indication segmentation underscores the nuanced requirements for targeting multiple sclerosis and rheumatoid arthritis within the broader autoimmune category, in addition to protocols optimized for leukemia and solid tumor management.

Lastly, technology segmentation contrasts continuous flow platforms with discontinuous flow alternatives, each offering trade-offs in processing time, cell yield, and procedural simplicity. These divergent approaches inform procurement decisions and clinical workflows, guiding manufacturers in aligning product roadmaps with end-user preferences.

Examining Regional Dynamics Shaping Global Growth

Regional dynamics underscore the variability of leukapheresis adoption and innovation ecosystems. In the Americas, a seasoned healthcare infrastructure, robust reimbursement frameworks, and a strong domestic manufacturing base have fostered widespread integration of advanced apheresis solutions. Major medical centers continue to invest in system upgrades, while regional distributors streamline logistics to maintain stable inventory levels.

Across Europe, Middle East and Africa, the market reflects a tapestry of regulatory landscapes and investment appetites. Western Europe benefits from harmonized approval processes and significant R&D funding, whereas emerging markets in the Middle East and Africa exhibit growing demand for outsourced clinical services and turnkey facility solutions. Strategic alliances and cross-border partnerships are increasingly common as stakeholders seek to overcome fragmented reimbursement and logistical hurdles.

In the Asia-Pacific region, expanding healthcare budgets and government-led modernization programs are driving rapid facility expansion. Clinical adoption is rising in both urban centers and secondary cities, supported by localized manufacturing initiatives that reduce dependency on imports. Furthermore, collaborative research programs between public institutions and private enterprises are accelerating the validation of leukapheresis applications in novel therapeutic areas.

Spotlighting Leading Innovators in Leukapheresis Market

The competitive landscape features established leaders alongside dynamic newcomers. Tier one manufacturers have solidified their positions through consistent investments in product innovation, integrating modular system designs that facilitate seamless upgrades and cross-compatibility with emerging consumables. Strategic mergers and acquisitions have allowed these players to broaden their portfolios and enhance service offerings, leveraging global distribution networks to maintain market dominance.

At the same time, specialized firms focusing on consumables and anticoagulant formulations are gaining traction by offering proprietary kits designed for niche protocols. These agile companies often collaborate with academic research centers to validate new use cases, translating laboratory breakthroughs into commercial solutions. Monitoring device innovators, meanwhile, are forging partnerships with digital health providers to embed analytics capabilities directly into the apheresis workflow. This confluence of pharmaceutical, device, and software expertise is reshaping competitive dynamics and creating fresh entry points for emergent players.

Strategic Actions for Industry Advancement and Resilience

To navigate an increasingly complex landscape, industry leaders must prioritize supply chain diversification to reduce exposure to policy shifts and geopolitical risks. By fostering relationships with alternate suppliers and investing in dual-sourcing strategies, organizations can sustain uninterrupted access to critical components while negotiating favorable terms. Concurrently, allocating R&D resources toward next-generation system enhancements-such as closed-loop feedback controls and AI-driven process optimization-will position companies at the forefront of procedural efficiency and patient safety.

Engaging in collaborative ventures with academic and clinical research institutions can unlock new therapeutic indications and validate novel protocols, accelerating regulatory approval timelines. Additionally, forging direct dialogues with policymakers and payers will facilitate the development of value-based pricing models that reflect the true clinical benefits of leukapheresis. Training initiatives for end users, incorporating virtual reality simulations and modular certification programs, will further drive adoption by reducing operational complexity and enhancing procedural confidence.

Robust Methodology Underpinning Comprehensive Analysis

The conclusions drawn herein are underpinned by a dual-tiered research methodology. Primary research entailed in-depth interviews with clinicians, procurement specialists, regulatory experts, and technology officers across diverse geographies. These qualitative engagements provided real-world perspectives on adoption barriers, clinical outcomes, and procurement strategies. Secondary research encompassed a thorough review of scientific journals, regulatory filings, patent disclosures, and industry white papers to contextualize technological advancements and policy developments.

Data triangulation ensured the validation of insights, with cross-referencing between interview feedback and published data bolstering confidence in trend identification. Segmentation criteria were defined to capture the heterogeneity of product types, applications, end-user requirements, disease indications, and technology platforms. Regional analyses were informed by an examination of healthcare infrastructure indices, reimbursement frameworks, and government initiatives. Finally, an impact assessment of 2025 tariff changes was conducted through policy analysis and supplier interviews, illuminating supply chain adaptations.

Concluding Insights and Future Outlook

In summary, the leukapheresis market is at a pivotal juncture, propelled by technological innovation and reshaped by evolving regulatory and policy landscapes. Segmentation analysis has revealed targeted avenues for product differentiation and service enhancement, while regional insights highlight the necessity of adaptive market entry strategies. Competitive intelligence underscores both the resilience of established players and the dynamism of specialized entrants, collectively driving continuous improvement in procedural performance and patient outcomes.

Industry leaders who embrace supply chain agility, invest in next-generation capabilities, and foster collaborative research partnerships will be best positioned to seize emerging opportunities. By aligning strategic priorities with actionable recommendations and leveraging the rigorous methodology that supports these findings, stakeholders can confidently navigate the complexities of the leukapheresis landscape and achieve sustainable growth.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Component
    • Consumables
      • Anticoagulants
      • Kits
    • Equipment
      • Apheresis Systems
      • Monitoring Devices
  • Application
    • Diagnostic
      • Blood Analysis
      • Immune Monitoring
    • Research
      • Cellular Therapy
      • Stem Cell Research
    • Therapeutic
      • Autoimmune
      • Oncology
  • End User
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Disease Indication
    • Autoimmune Diseases
      • Multiple Sclerosis
      • Rheumatoid Arthritis
    • Leukemia
    • Solid Tumors
  • Technology
    • Continuous Flow
    • Discontinuous Flow
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Terumo BCT, Inc.
  • Fresenius Kabi AG
  • Haemonetics Corporation
  • Macopharma SA
  • Miltenyi Biotec GmbH
  • B. Braun Melsungen AG
  • Grifols, S.A.
  • Asahi Kasei Medical Co., Ltd.
  • Sebia S.A.
  • Danaher Corporation

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Leukapheresis Market, by Component
8.1. Introduction
8.2. Consumables
8.2.1. Anticoagulants
8.2.2. Kits
8.3. Equipment
8.3.1. Apheresis Systems
8.3.2. Monitoring Devices
9. Leukapheresis Market, by Application
9.1. Introduction
9.2. Diagnostic
9.2.1. Blood Analysis
9.2.2. Immune Monitoring
9.3. Research
9.3.1. Cellular Therapy
9.3.2. Stem Cell Research
9.4. Therapeutic
9.4.1. Autoimmune
9.4.2. Oncology
10. Leukapheresis Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Research Institutes
10.4. Specialty Clinics
11. Leukapheresis Market, by Disease Indication
11.1. Introduction
11.2. Autoimmune Diseases
11.2.1. Multiple Sclerosis
11.2.2. Rheumatoid Arthritis
11.3. Leukemia
11.4. Solid Tumors
12. Leukapheresis Market, by Technology
12.1. Introduction
12.2. Continuous Flow
12.3. Discontinuous Flow
13. Americas Leukapheresis Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Leukapheresis Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Leukapheresis Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Terumo BCT, Inc.
16.3.2. Fresenius Kabi AG
16.3.3. Haemonetics Corporation
16.3.4. Macopharma SA
16.3.5. Miltenyi Biotec GmbH
16.3.6. B. Braun Melsungen AG
16.3.7. Grifols, S.A.
16.3.8. Asahi Kasei Medical Co., Ltd.
16.3.9. Sebia S.A.
16.3.10. Danaher Corporation
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. LEUKAPHERESIS MARKET MULTI-CURRENCY
FIGURE 2. LEUKAPHERESIS MARKET MULTI-LANGUAGE
FIGURE 3. LEUKAPHERESIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL LEUKAPHERESIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL LEUKAPHERESIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LEUKAPHERESIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LEUKAPHERESIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. LEUKAPHERESIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. LEUKAPHERESIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. LEUKAPHERESIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LEUKAPHERESIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LEUKAPHERESIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LEUKAPHERESIS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LEUKAPHERESIS MARKET SIZE, BY KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LEUKAPHERESIS MARKET SIZE, BY APHERESIS SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LEUKAPHERESIS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL LEUKAPHERESIS MARKET SIZE, BY BLOOD ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL LEUKAPHERESIS MARKET SIZE, BY IMMUNE MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL LEUKAPHERESIS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL LEUKAPHERESIS MARKET SIZE, BY CELLULAR THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL LEUKAPHERESIS MARKET SIZE, BY STEM CELL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL LEUKAPHERESIS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL LEUKAPHERESIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL LEUKAPHERESIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL LEUKAPHERESIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL LEUKAPHERESIS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL LEUKAPHERESIS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL LEUKAPHERESIS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL LEUKAPHERESIS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL LEUKAPHERESIS MARKET SIZE, BY CONTINUOUS FLOW, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL LEUKAPHERESIS MARKET SIZE, BY DISCONTINUOUS FLOW, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES LEUKAPHERESIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. CANADA LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 67. CANADA LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 68. CANADA LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 69. CANADA LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. CANADA LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 71. CANADA LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 72. CANADA LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 73. CANADA LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. CANADA LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 75. CANADA LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 76. CANADA LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 77. MEXICO LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 78. MEXICO LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 79. MEXICO LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 80. MEXICO LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. MEXICO LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 82. MEXICO LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 83. MEXICO LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 84. MEXICO LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. MEXICO LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 86. MEXICO LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 87. MEXICO LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 133. GERMANY LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 134. GERMANY LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 135. GERMANY LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 136. GERMANY LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. GERMANY LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 138. GERMANY LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 139. GERMANY LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 140. GERMANY LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. GERMANY LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 142. GERMANY LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 143. GERMANY LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 144. FRANCE LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 145. FRANCE LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 146. FRANCE LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 147. FRANCE LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. FRANCE LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 149. FRANCE LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 150. FRANCE LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 151. FRANCE LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. FRANCE LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 153. FRANCE LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 154. FRANCE LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. ITALY LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 167. ITALY LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 168. ITALY LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 169. ITALY LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. ITALY LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 171. ITALY LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 172. ITALY LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 173. ITALY LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. ITALY LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 175. ITALY LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 176. ITALY LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. SPAIN LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 178. SPAIN LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 179. SPAIN LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 180. SPAIN LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. SPAIN LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 182. SPAIN LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 183. SPAIN LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 184. SPAIN LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. SPAIN LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 186. SPAIN LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 187. SPAIN LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. DENMARK LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 222. DENMARK LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 223. DENMARK LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 224. DENMARK LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. DENMARK LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 226. DENMARK LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 227. DENMARK LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 228. DENMARK LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. DENMARK LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 230. DENMARK LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 231. DENMARK LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 243. QATAR LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 244. QATAR LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 245. QATAR LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 246. QATAR LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. QATAR LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 248. QATAR LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 249. QATAR LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 250. QATAR LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. QATAR LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 252. QATAR LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 253. QATAR LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 254. FINLAND LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 255. FINLAND LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 256. FINLAND LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 257. FINLAND LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 258. FINLAND LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 259. FINLAND LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 260. FINLAND LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 261. FINLAND LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. FINLAND LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 263. FINLAND LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 264. FINLAND LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 265. SWEDEN LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 266. SWEDEN LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 267. SWEDEN LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 276. NIGERIA LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 277. NIGERIA LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 278. NIGERIA LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 279. NIGERIA LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 287. EGYPT LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 288. EGYPT LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 289. EGYPT LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 290. EGYPT LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 291. EGYPT LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 292. EGYPT LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 293. EGYPT LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 294. EGYPT LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. EGYPT LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 296. EGYPT LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 297. EGYPT LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 298. TURKEY LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 299. TURKEY LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 300. TURKEY LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 301. TURKEY LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 302. TURKEY LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 303. TURKEY LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 304. TURKEY LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 305. TURKEY LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. TURKEY LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 307. TURKEY LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 308. TURKEY LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 310. ISRAEL LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 319. ISRAEL LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 320. NORWAY LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 321. NORWAY LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 322. NORWAY LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 323. NORWAY LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 324. NORWAY LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 325. NORWAY LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 326. NORWAY LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 327. NORWAY LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 328. NORWAY LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 329. NORWAY LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 330. NORWAY LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 331. POLAND LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 332. POLAND LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 333. POLAND LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 334. POLAND LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 335. POLAND LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 336. POLAND LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 337. POLAND LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 338. POLAND LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 339. POLAND LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 340. POLAND LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 341. POLAND LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 342. SWITZERLAND LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 343. SWITZERLAND LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 344. SWITZERLAND LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 345. SWITZERLAND LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 346. SWITZERLAND LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 347. SWITZERLAND LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 348. SWITZERLAND LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 349. SWITZERLAND LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 350. SWITZERLAND LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 351. SWITZERLAND LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 352. SWITZERLAND LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 353. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 354. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 355. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 356. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 357. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 358. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 359. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 360. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 361. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 362. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 363. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 364. ASIA-PACIFIC LEUKAPHERESIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 365. CHINA LEUKAPHERESIS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 366. CHINA LEUKAPHERESIS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 367. CHINA LEUKAPHERESIS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 368. CHINA LEUKAPHERESIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 369. CHINA LEUKAPHERESIS MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 370. CHINA LEUKAPHERESIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 371. CHINA LEUKAPHERESIS MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 372. CHINA LEUKAPHERESIS MARKET SIZE, BY END USER, 2018-

Companies Mentioned

The companies profiled in this Leukapheresis market report include:
  • Terumo BCT, Inc.
  • Fresenius Kabi AG
  • Haemonetics Corporation
  • Macopharma SA
  • Miltenyi Biotec GmbH
  • B. Braun Melsungen AG
  • Grifols, S.A.
  • Asahi Kasei Medical Co., Ltd.
  • Sebia S.A.
  • Danaher Corporation

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 67.79 Million
Forecasted Market Value ( USD ) by 2030 $ 107.68 Million
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Leukapheresis Market Size, Share & Trends Analysis Report By Product Type (Leukapheresis Devices, Leukapheresis Disposables), By Application (Research Application, Therapeutic Application), By End-use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Leukapheresis Market Size, Share & Trends Analysis Report By Product Type (Leukapheresis Devices, Leukapheresis Disposables), By Application (Research Application, Therapeutic Application), By End-use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Leukapheresis Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Leukapheresis Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 157 Pages
  • Global
From
Leukapheresis Market by Product, by Application, by End-User, and By Region - Product Image

Leukapheresis Market by Product, by Application, by End-User, and By Region

  • Report
  • 200 Pages
  • Global
From
Leukapheresis - Global Strategic Business Report - Product Image

Leukapheresis - Global Strategic Business Report

  • Report
  • 179 Pages
  • Global
From
Leukapheresis Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Leukapheresis Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 94 Pages
  • Global
From

About the Leukapheresis Market

Leukapheresis is a process used in hematology to separate white blood cells from other components of the blood. It is used to reduce the number of white blood cells in a patient's blood, which can be beneficial in the treatment of certain blood disorders. The process involves the use of a machine to separate the white blood cells from the other components of the blood, which are then returned to the patient. The white blood cells are then collected and stored for further use. Leukapheresis is used in the treatment of a variety of hematological conditions, including leukemia, lymphoma, and multiple myeloma. It is also used to reduce the risk of infection in patients undergoing chemotherapy or bone marrow transplantation. The leukapheresis market is composed of a variety of companies that provide products and services related to the process. These include companies that manufacture the machines used in the process, as well as those that provide the necessary supplies and services. Examples of companies in the leukapheresis market include Fresenius Medical Care, Haemonetics Corporation, Terumo BCT, and Asahi Kasei Medical. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.